domingo, 23 de agosto de 2009
Hilton Chaves assume compromisso com o DCM
Psicóloga enaltece as qualidades de Hilton
Rosane Nascimento e Silva, psicóloga e diretora do CPPL (Centro de Pesquisa em Psicanálise e Linguagem, Recife/PE).
Gravatá apoia Hilton Chaves para a SBC
Hilton estamos com você pela sua idoneidade e competência.
José Roberto da Silva, médico e Secretário Adjunto de Saúde de Gravatá-PE.
sábado, 15 de agosto de 2009
O Coração bate mais forte no Seu Dia
segunda-feira, 10 de agosto de 2009
Interamericano de Hipertensão é sucesso em BH
Foto: Hilton Chaves entre os Professores Ian Wilkinson (esquerda) e John Crockcoft.
quarta-feira, 5 de agosto de 2009
Clopidogrel plus aspirin versus oral anticoagulation for atrial
Este é o resumo de um artigo científico recomendado pelo Dr. Hilton Chaves.
Summary
Background: Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fi brillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events.
Methods: Patients were enrolled if they had atrial fi brillation plus one or more risk factor for stroke, and were randomly allocated to receive oral anticoagulation therapy (target international normalised ratio of 2·0–3·0; n=3371) or clopidogrel (75 mg per day) plus aspirin (75–100 mg per day recommended; n=3335). Outcome events were adjudicated by a blinded committee. Primary outcome was fi rst occurrence of stroke, non-CNS systemic embolus, myocardial infarction, or vascular death. Analyses were by intention-to-treat. This study is registered with
ClinicalTrials.gov, number NCT00243178.
Results: The study was stopped early because of clear evidence of superiority of oral anticoagulation therapy. There were 165 primary events in patients on oral anticoagulation therapy (annual risk 3·93%) and 234 in those on clopidogrel plus aspirin (annual risk 5·60%; relative risk 1·44 (1·18–1.76; p=0.0003). Patients on oral anticoagulation therapy who were already receiving this treatment at study entry had a trend towards a greater reduction in vascular events (relative risk 1·50, 95% CI 1·19–1·80) and a signifi cantly (p=0·03 for interaction) lower risk of major bleeding with oral anticoagulation therapy (1.30; 0.94–1.79) than patients not on this treatment at study entry (1·27, 0·85–1·89 and 0·59, 0·32–1·08, respectively).
Conclusion: Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fi brillation at high risk of stroke, especially in those already taking oral anticoagulation therapy.
domingo, 2 de agosto de 2009
Hilton Chaves empolga platéia no congresso Norte-Nordeste em Natal


